Source:http://linkedlifedata.com/resource/pubmed/id/17533523
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2007-5-29
|
pubmed:abstractText |
The aim of the present study was to investigate outcomes of implantable cardioverter-defibrillator (ICD) treatment in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). We reviewed baseline/follow-up data of 15 consecutive ARVC patients (mean age 55 +/- 15 years) and 30 randomly drawn patients with coronary artery disease (CAD) (mean age 60 +/- 10 years) with matching durations of follow-up (all implanted with ICDs for primary/secondary prevention of sudden death). At implant, appropriate placement of the RV lead was more difficult in ARVC patients. During follow-up (median 41 months), appropriate interventions for any ventricular tachyarrhythmias occurred in 8 (53%) ARVC patients and 17 (57%) CAD patients, but the occurrence of high rate (>240 beats/min) ventricular tachyarrhythmias was higher in ARVC patients. Inappropriate ICD interventions occurred in 5 (33%) ARVC patients and 10 (33%) CAD patients. Lead-related adverse events requiring surgical revision occurred in 7 (47%) ARVC patients as compared with 4 (13%) CAD patients (P = 0.0004). While ICD implantation is highly effective for prevention of sudden death in ARVC, it does carry elevated burdens of long-term lead-related adverse events. These findings underline the need of careful follow-up in ARVC aimed at early recognition of complications that can impair ICD function.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0910-8327
|
pubmed:author |
pubmed-author:ArtalePaoloP,
pubmed-author:BertiniMatteoM,
pubmed-author:BiffiMauroM,
pubmed-author:BorianiGiuseppeG,
pubmed-author:BranziAngeloA,
pubmed-author:DiembergerIgorI,
pubmed-author:FrabettiLorenzoL,
pubmed-author:MartignaniCristianC,
pubmed-author:ParlapianoMarioM,
pubmed-author:RapezziClaudioC,
pubmed-author:ValzaniaCinziaC,
pubmed-author:ZiacchiMatteoM
|
pubmed:issnType |
Print
|
pubmed:volume |
22
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
184-92
|
pubmed:meshHeading |
pubmed-meshheading:17533523-Adolescent,
pubmed-meshheading:17533523-Adult,
pubmed-meshheading:17533523-Aged,
pubmed-meshheading:17533523-Anti-Arrhythmia Agents,
pubmed-meshheading:17533523-Arrhythmogenic Right Ventricular Dysplasia,
pubmed-meshheading:17533523-Combined Modality Therapy,
pubmed-meshheading:17533523-Defibrillators, Implantable,
pubmed-meshheading:17533523-Female,
pubmed-meshheading:17533523-Humans,
pubmed-meshheading:17533523-Male,
pubmed-meshheading:17533523-Middle Aged,
pubmed-meshheading:17533523-Survival Rate,
pubmed-meshheading:17533523-Treatment Outcome
|
pubmed:year |
2007
|
pubmed:articleTitle |
Outcome of cardioverter-defibrillator implant in patients with arrhythmogenic right ventricular cardiomyopathy.
|
pubmed:affiliation |
Istituto di Cardiologia, Università di Bologna, Policlinico S. Orsola-Malpighi, via Massarenti 9, 40138, Bologna, Italy. giuseppe.boriani@unibo.it
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|